Discovery of Ovarian Cancer Biomarkers Using Biotinylated Antibodies
Author Information
Author(s): Nathalie Scholler, Jennifer A. Gross, Barbara Garvik, Lance Wells, Yan Liu, Christian M. Loch, Arturo B. Ramirez, Martin W. McIntosh, Paul D. Lampe, Nicole Urban
Primary Institution: University of Pennsylvania
Hypothesis
Can we identify novel serum biomarkers for ovarian cancer using biotinylated recombinant antibodies?
Conclusion
The study successfully identified PEBP1 and other proteins as potential biomarkers for ovarian cancer.
Supporting Evidence
- PEBP1 was detected in 29 out of 30 ascites samples.
- Independent evidence for ovarian cancer-specific expression of PEBP1 was found by ELISA assays.
- PEBP1 discriminated ovarian cancer sera from controls with statistical significance.
Takeaway
Researchers found new markers in the blood that can help detect ovarian cancer early.
Methodology
The study used yeast-display technology to isolate antibodies and mass spectrometry to analyze serum proteins.
Potential Biases
Potential bias in biomarker discovery due to epitope recognition by selected antibodies.
Limitations
The study did not identify well-known ovarian cancer markers like CA125 or HE4.
Participant Demographics
Included 31 serous ovarian cancer cases and 34 controls, with ages ranging from 42 to 87 years.
Statistical Information
P-Value
0.02
Statistical Significance
p = 0.02
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website